First IMI review meeting: The reviewers praised our impressive work! Despite hiccups such as Brexit, COVID, lockdowns and cyber-attacks, the consortium found the balance needed to continue the work and create results. Thank you Mobilise-D team for this great achievement!

EMA public letter of support for Mobilise-D: This public support endorses our initial stage in the wider objective to pursue the qualification of Digital Mobility Outcomes (DMOs) as monitoring biomarkers of mobility performance in regulatory drug trials.

Real World Stories – Ep.1: Read how our “Why Mobility matters” video had a direct impact on Gottfried’s daily life here!

TVS Milestone: The Technical Validation Study officially started recruiting patients in August and has now reached 60% recruitment.

The NIHR, UK, featured Mobilise-D as a case study for how to start-up research again, despite the ongoing global pandemic.

New videos: We made 6 videos this year, with “Why Mobility matters - now more than ever” as the most viewed. Check out all our videos on our YouTube channel!

New publications: This year, we’ve had no less than 12 Mobilise-D publications, 3 of them were major core Mobilise-D publications. You find them here.

Award and Honors: Claudia Mazza received the Suffrage Science award 2020, Lynn Rochester a NIHR Senior Investigator award, and Beatrix Vereijken was voted into the ISPGR Board.

Advent Calendar: Thank you to all the wonderful people that participated in our Advent Calendar. We hope you enjoyed it as much as we did, and that you got to know your colleagues a bit better!

Happy New Year! We hope you have a safe, happy and healthy holiday season. The very best wishes for 2021 and we look forward to continuing to work with you next year.

Mobilise-D has received funding from IMI 2 Joint Undertaking under grant agreement No. 820820. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).